Urology

Radiomics has been proven effective for the characterisation of primary prostate cancer (PCa).1,2 However, the limited interpretability of the proposed models represents one of the major limitations in this field.

Renal cell carcinoma (RCC) is the most common malignant kidney tumour, with clear cell RCC (ccRCC) accounting for 70–80% of all cases. Approximately 15–20% of patients have primary metastatic RCC at diagnosis, and 15–20% of those who receive curative treatment for localised tumours will experience recurrence within 5 years of follow-up.

Urothelial carcinoma in situ (CIS) of the bladder is an intra-epithelial, high grade, malignant neoplasm characterised by flat (non-papillary) growth, with high probability of disease progression.

Imparting the required psychomotor skills for trainees to become proficient in percutaneous nephrolithotomy (PCNL) and retrograde intrarenal surgery (RIRS) is tricky for surgical educators due to the challenging nature of the procedures and the lack of realistic simulators.

The following highlights cover several innovative and thought-provoking abstracts from the 37th European Association of Urology (EAU) featuring topics such as intravesical treatment in non-muscle invasive bladder cancer, artificial intelligence in recurrent urinary tract infections, and genetic risk in benign prostatic hyperplasia.

Hospital-acquired infections represent a global healthcare crisis, contributing to patient morbidity and mortality.

The Acute Cystitis Symptom Score (ACSS) is a patient self-reporting questionnaire for the clinical diagnostics and patient-reported outcome that may assess the symptoms and the effect on the quality of life in women with acute uncomplicated cystitis.

The diagnosis of pudendal neuropathy is based on a set of five criteria; four of them are clinical and the last one…